Stock Titan Trading tools for traders and investors.

-

08:31:11 AM

Last ADMP Stock Market News

ADMP - Adamis Pharmaceuticals Corp

02/22/21 9:00 AM

Nasdaq : ADMP

Adamis Pharmaceuticals Cleared to Proceed with Human Studies of Tempol for the Treatment of COVID-19

Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) ("Company") announced today that the U.S. Food and Drug Administration ("FDA") has completed the safety review of the Company's Investigational New Drug ("IND") application and has concluded that Adamis

RHEA-AI

neutral

02/17/21 9:00 AM

Nasdaq : ADMP

Adamis Pharmaceuticals Strengthens Patent Portfolio for Its Naloxone Product Candidate

Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) ("Company") today announced that it recently received a notice that one of its patent applications relating to its ZIMHI (TM) high dose naloxone injection product candidate, intended for the treatment of

RHEA-AI

neutral

01/29/21 9:00 AM

Nasdaq : ADMP

Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease,

RHEA-AI

neutral

01/28/21 4:01 PM

Nasdaq : ADMP

Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock

Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease,

RHEA-AI

neutral

01/28/21 9:00 AM

Nasdaq : ADMP

Adamis Pharmaceuticals and Human Immune Monitoring Center at Stanford University Announce Preliminary Tempol Data in Cells from COVID-19 Patients

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) ("Adamis") in collaboration with the Human Immune Monitoring Center at Stanford University have conducted a study to investigate the effects of Tempol on immune cells from COVID-19 patients. Preliminary

RHEA-AI

neutral

01/26/21 9:00 AM

Nasdaq : ADMP

Adamis Pharmaceuticals Provides Update On Its US Compounding Business

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has entered into a non-binding letter of intent with a potential buyer for sale of substantially all of the assets of its US Compounding Inc. (USC) subsidiary. Under the terms

RHEA-AI

neutral

01/25/21 8:45 AM

Nasdaq : INFI, ADMP, VBLT

Immunotherapy Using Immune-Checkpoint Inhibitors (ICI) Modulators Are Revolutionizing Oncology Industry

Ovarian cancer is one of the most deadly gynecologic malignancy across the globe, but new treatments are gaining increased efficacy while displaying reduced toxicity. Clinical trials abound. Immunotherapy using immune-checkpoint modulators has been

RHEA-AI

neutral

01/21/21 4:05 PM

Nasdaq : ADMP

SYMJEPI Products Now Available in the Walgreens Prescription Savings Club, with the Lowest Prices for Epinephrine Products

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its SYMJEPI (R) (epinephrine) Injection products are now available to members of the Walgreens Prescription Savings Club program, for a discounted price of $99.99 for a two-pack, the

RHEA-AI

negative

01/20/21 9:00 AM

Nasdaq : ADMP

Adamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) ("Adamis") announced today the submission of an Investigational New Drug (IND) to FDA for the investigational use of Tempol for the treatment of Coronavirus (COVID-19). The submission of the IND to FDA

RHEA-AI

negative

12/01/20 9:00 AM

Nasdaq : ADMP

Adamis Pharmaceuticals Describes Planned Response to ZIMHI Complete Response Letter

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced a planned response to a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA), regarding its New Drug Application (NDA) for Adamis' ZIMHI (TM) high dose naloxone

RHEA-AI

neutral